Minnesota Oncology

Colon Cancer News

Predicting SIR-Spheres® microspheres Treatment Outcomes for Metastatic Colorectal Cancer (March 5, 2014)

Pre-treatment laboratory tests may play a key role in predicting patient outcomes prior to selective internal radiation therapy for metastatic colorectal cancer, while a new modeling technology for enhancing delivery of treatment could improve treatment... Continue Reading

Stool Test Spots Most Colon Cancers (February 19, 2014)

A stool test known as the fecal immunochemical test (FIT) is accurate in diagnosing most colorectal cancers, according to a meta-analysis published in the Annals of Internal Medicine. Screening is crucial for the prevention and early detection of colorectal... Continue Reading

Genomic Health Announces Results of Oncotype DX(R) Colon Cancer Studies Presented at 2014 American Society of Clinical Oncology Gastrointestinal Cancer (ASCO GI) Symposium (February 7, 2014)

New data show real-life impact of Oncotype DX on treatment decisions, underscore clinical validity and utility of the test REDWOOD CITY, Calif., Jan. 29, 2014 /PRNewswire/ — Genomic Health, Inc. (Nasdaq: GHDX) today announced results from the Oncotype... Continue Reading

Oncotype DX Changes Treatment Recommendations in Stage II Colon Cancer (December 26, 2013)

Use of the Oncotype DX® colon cancer test changed treatment recommendations in 29 percent of stage II colon cancer patients, according to the results of a study published in Current Medical Research and Opinion. Stage II colon cancer refers to cancer... Continue Reading

Colorectal Cancer Screening Works Over Long-Term (October 4, 2013)

The results of a study published in the New England Journal of Medicine, suggest that it pays to follow colorectal cancer screening recommendations—and people who do follow the guidelines are less likely to develop colon cancer than people who do not. Colorectal... Continue Reading

End-of-Life Care Remains Aggressive, Despite Patient Wishes (September 16, 2013)

Although most patients with advanced cancer prefer hospice or palliative care that minimizes symptoms, many continue to receive aggressive treatment during their final weeks and months of life. In fact, elderly patients with advanced cancer often receive... Continue Reading

Low-Dose Aspirin Reduces Colon Cancer Risk in Women (August 7, 2013)

Women who take a low-dose aspirin every other day have a reduced risk of colon cancer, according to the results of a study published in the Annals of Internal Medicine—however, the benefit carries with it a risk of gastrointestinal bleeding.[1] Colorectal... Continue Reading

Biomarker Could Potentially Help Detect Colorectal Cancer (July 29, 2013)

Blood levels of miR-21, a piece of DNA known as microRNA, could serve as a promising biomarker for the early detection and prognosis of colorectal cancer, according to the results of a study published in the Journal of the National Cancer Institute. Colorectal... Continue Reading

Aspirin’s Preventive Effect for Colorectal Cancer Linked to Genotype (July 24, 2013)

Aspirin’s preventive effect for colorectal cancer may be limited to tumors without a genetic mutation known as BRAF, according to the results of a study published in the Journal of the American Medical Association.[1] Colorectal cancer remains the... Continue Reading

Genomic Testing May Reduce Medical Costs for Colon Cancer (June 14, 2013)

Use of the Oncotype DX® colon cancer test to guide treatment decisions may reduce medical costs and improve patient well-being. These results were presented at the 2013 Annual Meeting of the American Society of Clinical Oncology (ASCO). The Oncotype... Continue Reading

Latest Colon Cancer News By Stage


Adjuvant (I-III, A-C) Colon Cancer

Genomic Health Announces Results of Oncotype DX(R) Colon Cancer Studies Presented at 2014 American Society of Clinical Oncology Gastrointestinal Cancer (ASCO GI) Symposium (February 7, 2014)

New data show real-life impact of Oncotype DX on treatment decisions, underscore clinical validity and utility of the test REDWOOD CITY, Calif., Jan. 29, 2014 /PRNewswire/ — Genomic Health, Inc. (Nasdaq: GHDX) today announced results from the Oncotype... Continue Reading

Oncotype DX Changes Treatment Recommendations in Stage II Colon Cancer (December 26, 2013)

Use of the Oncotype DX® colon cancer test changed treatment recommendations in 29 percent of stage II colon cancer patients, according to the results of a study published in Current Medical Research and Opinion. Stage II colon cancer refers to cancer... Continue Reading

Genomic Testing May Reduce Medical Costs for Colon Cancer (June 14, 2013)

Use of the Oncotype DX® colon cancer test to guide treatment decisions may reduce medical costs and improve patient well-being. These results were presented at the 2013 Annual Meeting of the American Society of Clinical Oncology (ASCO). The Oncotype... Continue Reading

Second Large Study Confirms Oncotype DX Can Predict Recurrence in Stage 2 Colon Cancer (April 22, 2013)

Results from the large CALGB 9581 clinical validation study of the Oncotype DX® colon cancer test confirm that Recurrence Score® (RS) results improve the ability to differentiate high recurrence risk disease from low recurrence risk disease, beyond... Continue Reading

Oncotype DX in Colon Cancer May Reduce Medical Costs and Improve Patient Wellbeing (February 20, 2013)

The results of two studies evaluating Oncotype DX were presented at the 2013 Gastrointestinal Cancers Symposium in San Francisco and the data indicated that the colon cancer test may reduce medical costs, improve patient wellbeing, and change treatment... Continue Reading

More Adjuvant (I-III, A-C) Colon Cancer

Screening/Prevention Colon Cancer

Stool Test Spots Most Colon Cancers (February 19, 2014)

A stool test known as the fecal immunochemical test (FIT) is accurate in diagnosing most colorectal cancers, according to a meta-analysis published in the Annals of Internal Medicine. Screening is crucial for the prevention and early detection of colorectal... Continue Reading

Genomic Health Announces Results of Oncotype DX(R) Colon Cancer Studies Presented at 2014 American Society of Clinical Oncology Gastrointestinal Cancer (ASCO GI) Symposium (February 7, 2014)

New data show real-life impact of Oncotype DX on treatment decisions, underscore clinical validity and utility of the test REDWOOD CITY, Calif., Jan. 29, 2014 /PRNewswire/ — Genomic Health, Inc. (Nasdaq: GHDX) today announced results from the Oncotype... Continue Reading

Colorectal Cancer Screening Works Over Long-Term (October 4, 2013)

The results of a study published in the New England Journal of Medicine, suggest that it pays to follow colorectal cancer screening recommendations—and people who do follow the guidelines are less likely to develop colon cancer than people who do not. Colorectal... Continue Reading

Low-Dose Aspirin Reduces Colon Cancer Risk in Women (August 7, 2013)

Women who take a low-dose aspirin every other day have a reduced risk of colon cancer, according to the results of a study published in the Annals of Internal Medicine—however, the benefit carries with it a risk of gastrointestinal bleeding.[1] Colorectal... Continue Reading

Biomarker Could Potentially Help Detect Colorectal Cancer (July 29, 2013)

Blood levels of miR-21, a piece of DNA known as microRNA, could serve as a promising biomarker for the early detection and prognosis of colorectal cancer, according to the results of a study published in the Journal of the National Cancer Institute. Colorectal... Continue Reading

More Screening/Prevention Colon Cancer

Stage IV (D)/Relapsed Colon Cancer

Predicting SIR-Spheres® microspheres Treatment Outcomes for Metastatic Colorectal Cancer (March 5, 2014)

Pre-treatment laboratory tests may play a key role in predicting patient outcomes prior to selective internal radiation therapy for metastatic colorectal cancer, while a new modeling technology for enhancing delivery of treatment could improve treatment... Continue Reading

Genomic Health Announces Results of Oncotype DX(R) Colon Cancer Studies Presented at 2014 American Society of Clinical Oncology Gastrointestinal Cancer (ASCO GI) Symposium (February 7, 2014)

New data show real-life impact of Oncotype DX on treatment decisions, underscore clinical validity and utility of the test REDWOOD CITY, Calif., Jan. 29, 2014 /PRNewswire/ — Genomic Health, Inc. (Nasdaq: GHDX) today announced results from the Oncotype... Continue Reading

Erbitux Plus Chemo Boosts Survival in Patients with Colorectal Cancer and Liver Metastases (May 29, 2013)

Adding Erbitux® (cetuximab) to standard chemotherapy might allow some patients with colorectal cancer and inoperable liver metastases to undergo successful surgical resection of the liver metastasis, according to the results of a study published in the Journal... Continue Reading

Combo Treatment Effective in Elderly Patients with Metastatic Colorectal Cancer (March 6, 2013)

Combination therapy with Avastin® (bevacizumab) and Xeloda® (capecitabine) may be an optimal first-line treatment for treatment-naïve older patients with metastatic colorectal cancer, according to the results of a study presented at the 2013 Gastrointestinal... Continue Reading

Neulasta Significantly Reduces Febrile Neutropenia Among Colorectal Cancer Patients Receiving Chemotherapy Plus Avasatin (February 25, 2013)

Neulasta® (pegfilgrastim) significantly reduced the incidence of grade 3/4 febrile neutropenia among patients with locally advanced or metastatic colorectal cancer who received chemotherapy with FOLFOX or FOLFIRI followed by Avastin® (bevacizumab),... Continue Reading

More Stage IV (D)/Relapsed Colon Cancer